Search PubMed⌕ Search

Biomedical subjects

Y Togo

Publications and source records attributed to Y Togo.

At least 37 records · Page 2Linked to original sources
PubMed1975

Alice strain live attenuated influenza (H3N2) vaccin in an elderly population.

The clinical and antibody responses to Alice strain (AS) live attenuated influenza A (H3N2) vaccine and killed parenteral (KP) bivalent influenza vaccine were compared in a randomly allocated group of 150 elderly volunteers. AS recipients experienced more symptoms but these were mild and short in duration. Rhinitis occurred in 45% and pain at injection site in 25% of the AS and KP groups, respectively. Influenza A (H3N2) serum hemmaglutination inhibition titer responses were significantly higher in KP vaccinees; 95% of KP AND 60% OF AS recipients with initial titers smaller than or equal to 1:16 had fourfold or greater titer rises. KP induced significantly higher nasal neutralization titers but the proportion with fourfold or greater responses was not significantly different. Previous studies have shown poor correlations between antibody levels induced by live influenza vaccines and protection. Natural and/or challenge studies are needed before efficacy of influenza vaccines can be established.

Aged↗
PubMed1973

Antiviral effect of 3, 4-dihydro-1-isoquinolineacetamide hydrochloride in experimental human rhinovirus infection.

Double-blind trials were conducted in volunteers to evaluate the efficacy of the prophylactic 3,4-dihydro-1-isoquinolineacetamide hydrochloride (DIQA) treatment against rhinovirus type 24 challenge. Ten men received a 7-day course of DIQA treatment and 11 men received a placebo. The intranasal viral challenge dose was 10 mean tissue culture infective doses. The oral administration of 1 g prechallenge and 2 g a day for 6 consecutive postchallenge days did not prevent the development of colds. Nine drug-treated men and 10 controls developed rhinovirus illness. However, the illnesses of the drug-treated men were mild. Rhinorrhea occurred less frequently and was more mild in the drug-treated group. The challenge virus was recovered from 80% of these subjects in both groups, but almost twice the number of challenge viruses were isolated from the controls than from the drug-treated men. The prophylactic DIQA therapy appears to suppress the cold syndrome and to reduce virus excretion, although its effect is marginal. Additional clinical trials are warranted to confirm the antirhinoviral effect of this drug.

Acetamides↗
PubMed1973

In vitro effect of virazole against influenza viruses.

The minimal inhibitory concentrations of Virazole against 32 mean tissue culture infective doses of three type A influenza strains including type A/England/42/72 (H3N2) and a type B strain in tissue culture were 0.1 and 0.05 mug/ml, respectively. The growth inhibition pattern by various Virazole concentrations of type A virus was similar to that of the type B virus. Virazole appears to be slightly more potent against the A/England/42/72 strain than are other antiinfluenzal agents.

Amides↗
PubMed1973

Low-Temperature-Adapted Influenza A2/AA/6/60 Virus Vaccine in Man.

Volunteers inoculated nasopharyngeally with liver A2/AA/6/60 virus grown in primary bovine kidney cell cultures at 25 C were asymptomatic but developed significant serum and respiratory secretory antibody responses. Viruses were not recovered from these volunteers who had a low or moderate level of prevaccination antibody titers.

Journal Article↗
PubMed1969

Evaluation of amantadine hydrochloride in the treatment of A2 influenzal disease.

Amantadine hydrochloride is the first drug to show promise as a practical anti-influenza agent. Several studies demonstrating a prophylactic effect in volunteers with induced A2 disease as well as in patients during A2 outbreaks have created the impetus for therapeutic trials. The widespread A2 influenza epidemic that occurred early in 1968 provided the opportunity for therapeutic evaluation in the USA.A total of 197 prison inmates with proven influenza agreed to participate in the 10-day double-blind evaluation of amantadine (100 mg, twice daily). Onset of therapy was approximately 20 hours after first subjective awareness of illness.Assessment of drug effectiveness was based on rapidity of resolution of illness. There was a significant increase in the number of drug-treated as against placebo patients in the "rapid resolver" group whereas individuals receiving placebo dominated the "slow resolver" group. Analysis of febrile responses indicated that amantadine-treated patients had significantly more rapid defervescence. Virus isolation studies revealed etiologically related virus in 90% of all volunteers during the first 5 days of therapy. It was apparent that clinical improvement was not correlated with disappearance of the virus. Nevertheless, the trials conducted during the influenza season of early 1968 indicated the therapeutic effect of amantadine hydrochloride. Administration of 100 mg, twice daily, for 10 days did not cause any adverse effects.

Amantadine↗